| 11/06/2012 | RIGEL PHARMACEUTICALS |
RIGL
| Report Phase 3 data from from OSKIRA-1, OSKIRA-2, and OSKIRA-3 trials of Fostamatinib |
Rheumatoid Arthritis
|
1H 2013
|
|
| 11/06/2012 | Synta Pharmaceuticals Corp. |
SNTA
| Report final progression free survival and updated overall survival data from Phase 2b portion of GALAXY trial of Ganetespib |
Non-small cell lung cancer
|
1H 2013
|
|
| 11/06/2012 | Infinity Pharmaceuticals Inc. |
INFI
| Report topline data from Phase 1b trial of Retaspimycin hydrochloride plus Everolimus |
Non-small cell lung cancer
|
1H 2013
|
|
| 11/06/2012 | Infinity Pharmaceuticals Inc. |
INFI
| Report topline overall survival data Phase 2 trial of Retaspimycin HCl plus Docetaxel |
Non-small cell lung cancer
|
1H 2013
|
|
| 11/06/2012 | Targacept Inc. |
TRGT
| Initiate Phase 2b study of TC-5214 |
Overactive bladder
|
1H 2013
|
|
| 11/05/2012 | Trius Therapeutics Inc. |
TSRX
| Initiate Phase 3 trial of Tedizolid phosphate |
Pneumonia
|
1H 2013
|
|
| 11/01/2012 | Idenix Pharmaceuticals Inc |
IDIX
| Begin Phase II trial of IDX719 in combination therapy |
Chronic Hepatitis C infection
|
1H 2013
|
|
| 11/01/2012 | Incyte Corporation |
INCY
| Report primary endpoint results from Phase IIb trial of Baricitinib |
Moderate to severe psoriasis
|
2013
|
|
| 10/25/2012 | Durata Therapeutics |
DRTX
| File NDA for Dalbavancin |
Acute bacterial skin and skin structure infections (ABSSSI)
|
1H 2013
|
|
| 10/25/2012 | ZIOPHARM Oncology Inc. |
ZIOP
| Report data from Phase 2 trial of Ad-RTS IL-12 in combination with oral activator ligand |
Advanced melanoma
|
1H 2013
|
|
| 10/25/2012 | Biomarin Pharmaceutical Inc. |
BMRN
| File IND for BMN-190 |
Batten disease
|
1H 2013
|
|
| 10/31/2012 | Neurocrine Biosciences Inc |
NBIX
| Complete Phase II trial of Elagolix |
Uterine fibroids
|
1H 2013
|
|
| 11/07/2012 | Santarus Inc. |
SNTS
| Submit BLA for Ruconest |
Acute attacks of angioedema
|
1H 2013
|
|
| 11/08/2012 | Tranzyme Inc. |
TZYM
| Report top-line results from second Phase 3 DIGEST study of TZP-102 |
Diabetic gastroparesis
|
1H 2013
|
|
| 11/08/2012 | POZEN Inc. |
POZN
| File NDA for PA32540 and PA8140 |
Secondary prevention of cardiovascular disease in patients at risk for aspirin-induced ulcers
|
1H 2013
|
|